glp-1 drug novo nordisk Ozempic is first FDA-approved for kidney disease The GLP-1 Race - VERUS

Progress in alternative strategies to combat antimicrobial resistance: Focus on antibiotics

Last updated: 12 Jun 2025 | 27108 Views | Warning

doi: 10.3389/fphys.2023.1281071 Received 21 August 2023 Accepted 16 October 2023 Published 31 October 2023 Volume 14 - 2023 Edited by Maria Cavinato, University of Innsbruck, Austria Reviewed by Eleni Mavrogonatou, National Centre of Scientific Research Demokritos, Greece Raghvendra K

States can decide whether to cover obesity drugs under Medicaid

Chronic tendinopathy that has persisted for months or years often requires longer treatment of 6 to 8 weeks or more

Topic Q&A will close to new questions on August 21, 2024, but will remain active for viewing until the BAA closes